Skip to Content
Morningstar

BioNTech SE ADR BNTX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$79.86 +1.10 (1.40%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat

Karen Andersen

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships. BioNTech has also used cash from its covid vaccine profits to acquire rights to a more diversified pipeline of biologic drug candidates in oncology, with launches potentially starting in 2026.

Read Full Report

Price vs Fair Value

View History
BNTX is trading at a 398% premium.
Price
$79.86
Fair Value
$423.00
Uncertainty
Very High
1-Star Price
$873.77
5-Star Price
$15.50
Economic Moat
Yhfyg
Capital Allocation
Sdxwcpw

Bulls Say, Bears Say

Bulls

BioNTech's pipeline, which relies on expertise in mRNA and bioinformatics, will be difficult to replicate by competitors.

Bears

BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BNTX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$78.76
Day Range
$79.38–81.50
52-Week Range
$78.02–125.83
Bid/Ask
$79.00 / $81.47
Market Cap
$19.25 Bil
Volume/Avg
594,056 / 750,691

Key Statistics

Price/Earnings (Normalized)
25.18
Price/Sales
6.51
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
2.57%

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
6,133
Website
https://www.biontech.de

Competitors

Valuation

View More
Metric
BNTX
JNJ
MRK
Price/Earnings (Normalized)
 25.1813.9257.99
Price/Book Value
 0.885.017.90
Price/Sales
 6.514.095.22
Price/Cash Flow
 —15.7518.35
Price/Earnings
BNTX
JNJ
MRK

Financial Strength

Metric
BNTX
JNJ
MRK
Quick Ratio
 10.950.840.68
Current Ratio
 11.381.171.25
Interest Coverage
 —23.573.97
Quick Ratio
BNTX
JNJ
MRK

Profitability

Metric
BNTX
JNJ
MRK
Return on Assets (Normalized)
 −0.14%12.64%5.22%
Return on Equity (Normalized)
 −0.15%31.72%13.56%
Return on Invested Capital (Normalized)
 −2.21%20.11%8.29%
Return on Assets
BNTX
JNJ
MRK
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
GhkvrwnqtNym$620.9 Bil
 Vertex Pharmaceuticals Inc
VRTX
QytcrppnnLxllnrg$121.4 Bil
 Regeneron Pharmaceuticals Inc
REGN
HwwxjfhgcNprkd$112.8 Bil
 Moderna Inc
MRNA
GsyvhdxdYhryz$44.4 Bil
 Alnylam Pharmaceuticals Inc
ALNY
KqjlfdcvMqvgkzw$31.5 Bil
 argenx SE ADR
ARGX
CnjskywrCxtn$25.8 Bil
 Biomarin Pharmaceutical Inc
BMRN
ZmfshlnvbJwjtwd$15.4 Bil
 United Therapeutics Corp
UTHR
NbnqpljvPjhh$13.8 Bil
 Royalty Pharma PLC Class A
RPRX
YcdtylzvmGxjrgkd$11.7 Bil

Sponsor Center